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Systemic lupus erythematosus (SLE or lupus) is one of 
the most common systemic autoimmune connective 
tissue diseases. It is characterized by a highly variable 
clinical presentation that may range from mild skin 
involvement to life-threatening multi-organ failure1,2. 
Some authorities from the government of a country such 
as The Japanese Ministry of Health, Labor and Welfare 
even designated SLE as an intractable disease because 
there is no established way to cure the existing disease, 
but with appropriate management3. 
Systemic lupus erythematosus is, without a doubt, a 
debilitating and life-altering illness. Systemic lupus 
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Systemic Lupus Erythematosus 
 Abstract 
The systemic lupus erythematosus (SLE), commonly known as Lupus, 
is a rare and complex multisystem autoimmune disease where one’s 
immune system is overactive, and the body attacks its organ systems. 
SLE is a historically old disease described already in antiquity; it is an 
example of a chronic disease with physical, psychological, financial, 
and social implications for individuals diagnosed. It has inspired 
medical and basic biological scientists that focus on molecular biology, 
basic immunology, immunopathology, clinical science, genetics, and 
epidemiology. The syndrome is real in its existence-although hidden 
behind obstacles, cumbersome for patients and clinicians, and 
rebellious for scientists. There is currently no cure for SLE. The goal of 
treatment is to ease symptoms. This article will review information on 
the general approach to SLE therapy, focusing on currently approved 
therapies and novel approaches that might be used in the future. 
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erythematosus may cause severe symptoms such as 
discomfort, excessive weakness, hair loss, cognitive 
problems, and physical impairments; many people with 
SLE develop cardiovascular disease, strokes, disfiguring 
rashes, and sore joints; and some people with SLE have 
no apparent symptoms4. The etiology of SLE has not yet 
been elucidated in detail, although genetic factors and 
environmental factors are thought to play a role in its 
development5. The discrepancies of rates (i.e., higher 
rates in certain ethnic groups) are due to genetic factors 
and environmental factors such as smoking and dietary 
habits6. 
The history of SLE goes back even further than the 4th-
century. Hippocrates recorded the documented case of 
lupus in 400 BC7. The four main types of lupus are 
neonatal and pediatric lupus erythematosus (NLE); 
cutaneous or discoid lupus erythematosus (CLE); drug-
induced lupus erythematosus (DILE); and SLE, as 
presented in Table I. Systemic lupus erythematosus can 
be divided into three periods: the classical period, the 
neoclassical period, and the modern period. Each period 
is marked with important discoveries that have allowed 
a better understanding of this disease8. This mini-review 
will discuss several things related to SLE and its clinical 
approach, including epidemiology, pathogenesis, 




The SLE is seen worldwide and occurs in all racial or 
ethnic groups, although regional variations in frequency 
and severity have been reported9. An estimated 5 million 
people worldwide have some form of lupus disease. The 
70% of lupus cases diagnosed are SLE, 20% of people 
with lupus will have a parent or sibling who already has 
lupus or may develop lupus, and about 5% of the 
children born to individuals with lupus will develop the 
illness10,11. Studies have shown that the incidence rate of 
SLE around the world is about 1 to 10 per 100000 
people/years12, while the prevalence rates range 3.2 cases 
per 100000 persons, with the highest prevalence reported 
in India, and it appears to be increasing as the disease is 
recognized more readily and survival increases13,14. In the 
US, people of African, Hispanic, or Asian ancestry as 
compared to those of other racial or ethnic groups, tend 
to have an increased prevalence of SLE and greater 
involvement of vital organs15-17. 
Table I. The four categories of lupus and their 
descriptions18,19 









Neonatal lupus erythematosus is a rare condition 
that affects infants of women who have lupus and 
is caused by antibodies (Abs) from the mother 
acting upon the infant in the uterus. At birth, the 
infant may have a skin rash, liver problems, or low 
blood cell counts, but these symptoms disappear 






This form of lupus is limited to the skin. Although 
CLE can cause many types of rashes and lesions 
(sores), the most common discoid rash is raised, 
scaly, and red, but not itchy. Areas of rash appear 
like disks or circles. Another typical e.g., of CLE is 
a rash over the cheeks and across the bridge of the 
nose. Hair loss and changes in the pigment, or 





The symptoms of DILE are similar to those of SLE, 
but it rarely affects major organs. DILE is a lupus-
like disease caused by certain prescription drugs 






Systemic lupus erythematosus is the most 
common form of lupus-it can be mild or severe—
some of the more severe complications involving 
major organ systems. Inflammation of the kidneys 
can affect the body’s ability to filter waste from the 
blood. Inflammation of the nervous system and 
the brain’s blood vessels can cause high fevers, 
seizures, behavioral changes, confusion, 
headaches, and strokes24. 
 
PATHOGENESIS 
The etiology of SLE is unknown to date. Many factors 
contribute to SLE development, including genetic, 
environmental, hormonal, and immunoregulatory 
factors25-27, as described in Figure 1. Certain risk factors 
have been identified and shown to contribute to disease 
susceptibility or activate the immune system causing an 
inflammatory response, ultimately leading to the 
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development of the disease28. Genetic factors influence 
predisposition to SLE. The female predominance in SLE 
may be explained, in part, by the contribution of certain 
hormones. Environmental factors, such as smoking, 
exposure to ultraviolet light, viral infections, and specific 
medications (e.g., sulfonamide antibiotics) are known to 
trigger SLE29. The pathogenesis of SLE is complex, with 
contributions from many components of the immune 
system. With the underlying genetic predisposition and 
in response to various triggers, the balance of the immune 
system shifts towards reacting against it rather than self-
tolerance30. The T and B cells become activated, leading to 
antibody production and eventual immune complex 
formation. These complexes circulate and deposit in 
critical tissues causing organ injury31. 
 




According to the American College of Rheumatology, 
the diagnosis of SLE is based on the clinical and 
laboratory criteria33, as summarized in Table II. The 
diagnosis of SLE requires four or more of the following 
eleven criteria during the observation34. Since the early 
signs and symptoms of SLE are non-specific and can 
mimic those of other diseases, for example, rheumatoid 
arthritis, glomerulonephritis, anemia, or dermatitis, it can 
be challenging to diagnose. The accuracy of diagnosis 
and early recognition of SLE is essential35,36. An algorithm 
for the diagnosis of the SLE shows in Figure 2. 






Fixed erythema, flat or raised, over the 
malar eminences, tending to spare the 
nasolabial folds. 
Discoid rash Erythematous, raised patches with 
adherent keratotic scaling and follicular 
plugging; possibly atrophic scarring in 
older lesions. 
Photosensitivity Skin rash as a result of unusual reaction 
to sunlight, as determined by patient 
history or physician observation. 
Oral ulcers Oral or nasopharyngeal ulceration, 
usually painless, observed by the 
physician 
Arthritis Non-erosive arthritis involving two or 
more peripheral joints, characterized by 
swelling, tenderness, or effusion. 
Serositis Pleuritis, by the convincing history of 
pleuritic pain, rub heard by a physician, 
or evidence of pleural effusion; or 
pericarditis documented by 
electrocardiography, rub heard by a 




Persistent proteinuria, 0.5 g/day or >3+ 
if quantitation is not performed; or 
cellular casts (maybe red blood cell, 




Seizures or psychosis occur in the 
absence of offending drugs or known 
metabolic derangement (e.g., uremia, 
ketoacidosis, electrolyte imbalance). 
Hematologic 
disorder 
Hemolytic anemia with reticulocytosis; 
or leukopenia, 4.0 x 109/L on two or 
more occasions; or lymphopenia, 1.5 x 
109/L on two or more occasions; or 
thrombocytopenia, 100 x 109/L in the 
absence of offending drugs. 
Immunologic 
disorder 
Antibody to a double-stranded 
deoxyribonucleic acid antigen (anti-
dsDNA) in abnormal titer; or presence 
of antibody to Smith nuclear antigen 
(anti-Sm); or positive finding of 
antiphospholipid Abs based on an 
abnormal serum level of 
Immunoglobulin (Ig) G or Ig M 
anticardiolipin Abs, a positive test result 
for lupus anticoagulant using a 
standard method, or a false positive 
serologic test for syphilis that is known 
to be positive for at least six months and 
is confirmed by negative Treponema 
pallidum immobilization or fluorescent 
treponemal antibody absorption test. 
Antinuclear 
antibodies 
An abnormal antinuclear antibodies 
(ANA) titer by immunofluorescence or 
an equivalent assay at any time and in 
the absence of drugs known to be 
associated with DILE. 
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Figure 2. Factors involved in the pathogenesis of SLE37 
 
TREATMENT 
There is no cure for SLE at present, but the condition is 
most often very treatable and usually responds well to 
some different types of drugs-especially when treatment 
is started in the early stages of the disease38. Most of the 
drugs described in Table III were initially developed for 
other diseases but were later found to be helpful in SLE39. 
There are many levels of severity and complications of 
SLE that require management. Treatment is dependent 
on presentation, and options include antimalarials, 
glucocorticoids, immunosuppressants, and biologics. 
NSAIDs may also be used to treat inflammation and pain 
enlisted40. 
In addition to these therapies, the current development of 
treatments for SLE has primarily led to the development 
of monoclonal antibodies41, as presented in Table IV. 
Two newer drugs (rituximab and belimumab) are now 
sometimes used for the treatment of severe SLE42. Also, 
several small-molecule inhibitors have shown promising 
progress in the treatment of SLE. Research is continuing 
to find out which patients respond best to these drugs43-
45. 
Table III. Common medications to control SLE 
Agents Descriptions 
NSAIDs Over-the-counter NSAIDs, such as 
naproxen sodium and ibuprofen may be 
used to treat pain, swelling, and fever 
associated with SLE. Stronger NSAIDs are 
available by prescription. 
Anti-
malarial 
Drugs commonly used to treat malaria, such 
as hydroxychloroquine, affect the immune 
system, and decrease the risk of SLE flares. 
Cortico-
steroids 
Prednisone and other types of 
corticosteroids can counter the 
inflammation of SLE. High doses of steroids 
such as methylprednisolone often used to 
control serious disease that involves the 
kidneys and brain. 
Immuno-
suppressants 
Drugs that suppress the immune system 
may be helpful in serious cases of SLE e.g. 
azathioprine and methotrexate. 
Biologics Biological agents used in the treatment of 
SLE include rituximab and belimumab, both 
monoclonal antibodies. Rituximab targets B 
cells and is used to treat renal and CNS 
presentations of SLE. This agent is 
recognized as an II- or III-line agent for 
active disease.  Belimumab targets the B cell-
activating factor B-lymphocyte stimulator. 
Belimumab is approved for use in active 
disease in conjunction with standard 
therapies including glucocorticoids, 
antimalarials, NSAIDs, mycophenolate 
mofetil, and azathioprine. Other biologics, 
such as tumor necrosis factor inhibitors, 
abatacept, and tocilizumab, are also 
considered. 
Other agents Besides the agents listed above, there are 
other agents used off-label to treat SLE. 
These include disease-modifying 
antirheumatic drugs such as methotrexate, 
leflunomide, and calcineurin inhibitors 
(tacrolimus and cyclosporine). 
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Table IV. Summary of new and emerging therapies or     
clinical trials in the treatment of SLE 




Belimumab Approved for non-renal SLE; 
Ongoing phase-IV for efficacy, 
safety, and tolerability; Ongoing 
phase-III in combination with 
Rituximab. 
Tabalumab Phase-III without significant effect 
(terminated). 




APRIL-SLE study terminated due 
to increased infection rate; 
ADDRESS-II study has an 
acceptable safety profile. 
CD20 Rituximab
  
Phase-III failed (nephritis and non-
nephritis). 
Ocrelizumab Phase-III trial completed. 
CD22  Epratuzumab Phase-III failed. 
CD19  XmAb5871 Phase-II trial. 
Proteasome 
inhibitors 
Bortezomib Phase-II trial. 
Intracellular signaling 
Btk M2951  Ongoing phase-II trial. 
Fenebrutinib  Ongoing phase-II trial. 
mTOR  N-
acetylcysteine  
A small study showed a decrease 
in SLEDAI, with no further 
development. 
Rapamycin  An open-label study showed an 
effect on BILAG. The larger study 
was planned. 
JAK/STAT GSK2586184 Ineffective interferon signature in 
phase-II, safety data do not 
support further study. 
JAK 2  Baricitinib  Phase-II positive data; Phase-III 
trial ongoing. 





Effective in preclinical studies in a 
patient with Raynaud's 
phenomenon, Phase-III completed 
with un-interpretable data. 
Co-stimulation 
CD40:CD154  Dapirolizumab  Ongoing phase-II trial. 
BI 655064  Ongoing phase-II trial. 
CD28: B7  Abatacept  Ineffective in Phase-III in nephritis 
and general SLE. 
Lulizumab  Phase-II trial terminated-failed to 
meet protocol objectives. 
Cytokines 
IFN-a Sifalimumab  The limited effect in phase-II and 
III. No further development. 
Rontalizumab  Phase-II without significant 
results. 
Anifrolumab  Phase-II positive data; 2 Phase-III 
trials ongoing (one reported 
negative). 
IAGS-009  Completed phase-I, no data 
released. 
JNJ-55920839  In recruiting phase. 




Aldesleukin  Ongoing open-label phase-II trial. 
AMG 592  Ongoing phase-Ib and IIa trial. 
ILT-101  Ongoing phase-II trial. 
IL-12/23  Ustekinumab  Met primary end-point in a phase-
II trial; ongoing phase-III trial. 
IL-6  PF-04236921  Failed phase-II trial; safety 
compromised. 
Sirukumab  Failed phase-II trial. 
MRA003US  Ongoing phase-II trial. 
Vobarilizumab  Ongoing phase-I trial. 
IL-10  BT063  Ongoing phase-II trial. 
Other 




Systemic lupus erythematosus is a chronic autoimmune 
inflammatory disorder that causes significant morbidity 
and mortality. The disease is a scientifically challenging, 
problematic, inspiring, and seminal, clinical syndrome. 
Systemic lupus erythematosus treatment has made 
significant progress over the past decade; however, the 
management of SLE is complex, with a multitude of 
complications and various treatment options. Patients 
require a comprehensive plan for care and management 
of complications from both the disease and therapy. Over 
the past few years, scientific studies and ongoing clinical 
trials have shifted the paradigm with rapid advances in 
developing biologics and small molecules. 
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